<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-12-15">December 15, 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Daphne</forename><surname>Gschwantler-Kaulich</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Cancer Comprehensive Center</orgName>
								<orgName type="institution">Medical University Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sigrid</forename><surname>Weingartshofer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Cancer Comprehensive Center</orgName>
								<orgName type="institution">Medical University Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christine</forename><surname>Rappaport-Fu ¨rhauser</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Cancer Comprehensive Center</orgName>
								<orgName type="institution">Medical University Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><surname>Zeilinger</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Cancer Comprehensive Center</orgName>
								<orgName type="institution">Medical University Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dietmar</forename><surname>Pils</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Section for Clinical Biometrics</orgName>
								<orgName type="department" key="dep2">Center for Medical Statistics, Informatics, and Intelligent Systems (CeMSIIS)</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Surgery</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Daniela</forename><surname>Muhr</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Cancer Comprehensive Center</orgName>
								<orgName type="institution">Medical University Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elena</forename><forename type="middle">I</forename><surname>Braicu</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Gynecology with Center for Oncological Surgery</orgName>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">European Competence Center for Ovarian Cancer</orgName>
								<orgName type="institution" key="instit1">Charite ´-Campus Virchow-Klinikum</orgName>
								<orgName type="institution" key="instit2">University Medicine of Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Marie-Therese</forename><surname>Kastner</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Cancer Comprehensive Center</orgName>
								<orgName type="institution">Medical University Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yen</forename><forename type="middle">Y</forename><surname>Tan</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Cancer Comprehensive Center</orgName>
								<orgName type="institution">Medical University Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">QIMR Berghofer Medical Research Institute</orgName>
								<address>
									<settlement>Herston QLD</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lorenz</forename><surname>Semmler</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Cancer Comprehensive Center</orgName>
								<orgName type="institution">Medical University Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jalid</forename><surname>Sehouli</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Gynecology with Center for Oncological Surgery</orgName>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">European Competence Center for Ovarian Cancer</orgName>
								<orgName type="institution" key="instit1">Charite ´-Campus Virchow-Klinikum</orgName>
								<orgName type="institution" key="instit2">University Medicine of Berlin</orgName>
								<address>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><forename type="middle">F</forename><surname>Singer</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Obstetrics and Gynecology</orgName>
								<orgName type="department" key="dep2">Cancer Comprehensive Center</orgName>
								<orgName type="institution">Medical University Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="institution" key="instit1">University Wexner Medical Center</orgName>
								<orgName type="institution" key="instit2">UNITED STATES</orgName>
							</affiliation>
						</author>
						<title level="a" type="main">Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-12-15">December 15, 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">A27E34E2A1780511C194BC57B3666CD3</idno>
					<idno type="DOI">10.1371/journal.pone.0189641</idno>
					<note type="submission">Received: May 28, 2017 Accepted: November 28, 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:35+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Screening for ovarian cancer (OC) in women at high risk consists of a combination of carbohydrate antigen 125 (CA125) and transvaginal ultrasound, despite their low sensitivity and specificity.</s><s>This could be improved by the combination of several biomarkers, which has been shown in average risk patients but has not been investigated until now in female BRCA mutation carriers.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>Using a multiplex, bead-based, immunoassay system, we analyzed the concentrations of leptin, prolactin, osteopontin, insulin-like growth factor II, macrophage inhibitory factor, CA125 and human epididymis antigen 4 in 26 healthy wild type women, 26 healthy BRCA1 mutation carriers, 28 wildtype OC patients and 26 OC patients with BRCA1 mutation.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Using the ROC analysis, we found a high overall sensitivity of 94.3% in differentiating healthy controls from OC patients with comparable results in the wildtype subgroup (sensitivity 92.8%, AUC = 0.988; p = 5.2e-14) as well as in BRCA1 mutation carriers (sensitivity 95.2%, AUC = 0.978; p = 1.7e-15) at an overall specificity of 92.3%.</s></p><p><s>The used algorithm also allowed to identify healthy BRCA1 mutation carriers when compared to healthy wildtype women (sensitivity 88.4%, specificity 80.7%, AUC = 0.895; p = 6e-08), while this was less pronounced in patients with OC (sensitivity 66.7%, specificity 67.8%, AUC = 0.724; p = 0.00065).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion</head><p><s>We have developed an algorithm, which can differentiate between healthy women and OC patients and have for the first time shown, that such an algorithm can also be used in BRCA</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Ovarian cancer is the most lethal cancer among gynaecological malignancies with a 5-year survival rate of patients diagnosed with advanced disease ranging from 20% to 25%.</s><s>Only 20% of patients are diagnosed at stage I and II because of missing screening strategies <ref type="bibr" target="#b0">[1]</ref>.</s></p><p><s>While the lifetime risk of developing OC in the general population is about 1% to 2%, women with deleterious BRCA mutations have a cumulative lifetime risk of developing OC of approximately 45% in BRCA1 carriers and 20% in BRCA2 carriers <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b2">3]</ref>.</s><s>While the early detection of breast cancer with the combination of mammography and MRI has a high success rate in this high risk population <ref type="bibr" target="#b3">[4]</ref>, the combination of transvaginal ultrasound (TVU) and CA125 for the early detection of ovarian cancer has suboptimal results.</s><s>CA125 has a sensitivity of less than 60% in early stage OC with moderate improvement by the addition of TVU <ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref>.</s></p><p><s>Furthermore, the incidence of serous tubal intraepithelial carcinomas (STIC) has been reported in a range from 0.6-7% in BRCA mutation carriers <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11]</ref>.</s><s>Therefore BRCA1 or BRCA2 mutation carriers are recommended to undergo risk reducing salpingo-oophorectomy (RRSO) by age 40 or after the completion of childbearing <ref type="bibr" target="#b11">[12]</ref>.</s><s>RRSO reduces the risk of OC by 85-90% and the risk of breast cancer by about 50% <ref type="bibr" target="#b12">[13]</ref> and may also impact cancer-specific and overall mortality <ref type="bibr" target="#b13">[14]</ref>.</s></p><p><s>Studies have reported rates of RRSO in BRCA mutation carriers ranging from 12% to 78% underlining the importance of exact information about benefits and possible side-effects of this intervention in the presence of psychooncologists, because recommendations for OC screening for those who choose to forego or delay RRSO, are conflicting <ref type="bibr" target="#b14">[15]</ref>.</s></p><p><s>Therefore a better screening program for the early detection of OC is warranted for a better surveillance during the childbearing period, as a stop gap solution until mutation carriers decide to undergo RRSO and for those carriers deciding to forego RRSO.</s></p><p><s>Limited data exist regarding the combination of biomarkers to improve the early detection of OC in BRCA mutation carriers, although promising results have been reported using the combination of HE4 with CA125 <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b16">17]</ref>.</s><s>Using a six biomarker panel consisting of macrophage inhibitory factor (MIF), prolactin, CA125, leptin, osteopontin and insulin like growth factor 2 (IGF2), Visintin et al reported an improved differentiation between disease free and ovarian cancer patients compared to CA125 alone in patients without a family history of OC (sensitivity of 95.3% vs 75%; specificity of 99.4% vs 95%) <ref type="bibr" target="#b17">[18]</ref>.</s><s>In this setting the combination of these six biomarkers with blood based gene expression achieved further improvement showing a sensitivity of 97.8% and a specificity of 99.6% <ref type="bibr" target="#b18">[19]</ref>.</s></p><p><s>To our knowledge, there exist no data evaluating the feasibility of the Milliplex 6-plex Ovarian Cancer Panel Kit combined with HE4 for the detection of ovarian cancer in BRCA mutation carriers.</s><s>We therefore evaluated the serum-concentrations of these seven biomarkers in healthy non carriers, healthy BRCA1 mutation carriers, patients with sporadic OC and BRCA1 mutation carriers with OC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics, consents</head><p><s>The ethical board of the Medical University of Vienna approved this study.</s><s>Patients had to sign an informed consent prior to inclusion into the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient population</head><p><s>Ovarian cancer group.</s><s>The disease group (n = 54) included wildtype women with newly diagnosed OC (n = 28) and BRCA1 mutation carriers with OC (n = 26).</s><s>Eleven samples of wildtype OC patients were obtained from the biobank of the Medical University of Vienna and 17 samples of wildtype OC patients as well as 26 samples of BRCA1 mutation carriers with OC from the tumorbank ovarian cancer (TOC) of the Charite ´, Medical University of Berlin.</s><s>Median age in the wildtype group was 57.6 yrs (33.6-82.1)</s><s>and in the BRCA1 mutation carrier group 53.0 yrs (41.0-78.0).</s><s>All samples were collected prior to surgery.</s><s>Table <ref type="table" target="#tab_0">1</ref> shows detailed information about histology and stage of the disease.</s></p><p><s>Control group.</s><s>The healthy control group (n = 52) included age-matched sera from healthy wildtype women (n = 26) and healthy BRCA1 mutation carriers (n = 26) obtained from the biobank of the Medical University of Vienna.</s><s>Median age in the healthy wildtype group was 67.1 yrs (60.7-72.4) and 36.4 yrs (26.4-61.7) in healthy BRCA1 mutation carriers.</s><s>We included only BRCA1 mutation carriers who have not undergone risk reducing surgery.</s><s>(Table <ref type="table" target="#tab_0">1</ref>)</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample collection</head><p><s>Ten mL of peripheral blood was drawn from subjects using standardized phlebotomy procedures <ref type="bibr" target="#b19">[20]</ref>.</s><s>Samples were processed within two to four hours using guidelines set by the National Cancer Institute Inter-Group Specimen Banking Committee and stored at -80˚C in the sera bank.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Multiplex analysis</head><p><s>Serum determinations for MIF, leptin, prolactin, OPN, CA125, and IGF II were performed using the beadlyte 6-plex Ovarian Cancer Panel Kit and a kit for the analysis of HE4, both from Millipore, according to the manufacturers instructions <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>.</s><s>The 6-plex Ovarian Cancer Panel Kit included two panels: one for prolactin, leptin, OPN, MIF and CA125 (Beadlyte 5-plex Ovarian Cancer Panel) and a separate panel for IGF-II (Beadlyte Anti-Human IGF-II Bead Set).</s><s>Because of data suggesting that HE4 plays a role in OC, we added a separate kit for the detection of HE4 (Beadlyte Anti-Human HE4 Bead Set).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>Missing Luminex values, i.e. values below analyte-specific detection limits, were imputed with analyte-corresponding PBS-values divided by square root of two.</s><s>The geometric mean of two calibrator samples were used as reference to level plate specific differences and all values were log-2 transformed to get (near) parametric distributions.</s></p><p><s>Statistical differences over all four/five groups (CTRL WT, CTRL BRCA, Ca WT, and Ca BRCA) were calculated by one-way analysis of variance (ANOVA) with subsequent-if significant-post-hoc tests according Tukey's 'Honest Significant Difference' method.</s><s>Multivariable discriminative models were built by logistic regressions and a cut-off defined by maximizing specificity and sensitivity simultaneously (R-package OptimalCutpoints).</s><s>Receiver Operating Characteristic (ROC) curves, corresponding area under these ROC curves (AUC), and p-values are presented.</s><s>(Two-sided) p-values below 0.05 were considered as statistically significant.</s><s>All analyses were performed with R version 3.3.3</s><s><ref type="bibr" target="#b20">[21]</ref> and R-packages: ROCR v1.0-7 <ref type="bibr" target="#b21">[22]</ref> and OptimalCutpoints v1.1-3 <ref type="bibr" target="#b22">[23]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Differentiation between healthy women and OC patients</head><p><s>We performed multiplex analysis and evaluated the serum determination of the seven biomarkers (CA125, MIF, Leptin, OPN, Prolactin, IGF2 and HE4) in healthy wildtype women, healthy women with BRCA1 germline mutation, wildtype OC patients and BRCA1 mutation carriers with OC.</s><s>Since 17 samples of patients with wildtype OC and 26 samples of BRCA1 mutation carriers with OC came from one institution (tumorbank ovarian cancer (TOC) of the Charite</s></p><p><s>´, Medical University of Berlin), we performed a test for interaction in order to identify possible laboratory or sampling bias.</s><s>We found no significant difference for CA125, leptin, OPN, MIF, IGF2 and HE4.</s><s>However, the prolactin levels in the respective subgroups differed significantly between the two centers and we therefore excluded prolactin from our algorithm (see S1 Fig We then adjusted our results for age and looked at correlations between the level of the investigated biomarkers and age (S2-S5 Figs, Table <ref type="table" target="#tab_1">2</ref>).</s><s>We found a positive correlation of MIF with age (R = 0.42, p&lt;0.05) and a negative correlation of IGF2 with age (R = -0.35,</s><s>p&lt;0.1) in the wildtype control group.</s><s>We found no such correlations in the BRCA1 groups where the difference in age between healthy mutation carriers and those with OC were significant.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Differentiation between wildtype women and BRCA1 mutation carriers</head><p><s>We then investigated if there are differences in the levels of these six biomarkers between wildtype women and BRCA1 mutation carriers.</s><s>In the healthy cohort, we found significant higher levels of CA125 (</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ROC Analysis</head><p><s>Since IGF2 levels were not available from all patients, we restricted our algorithm to five biomarkers (MIF, Leptin, CA125, OPN and HE4) using area under the receiver operating charactersistic (ROC) curves (AUCs).</s><s>When we evaluated the value of the five biomarkers in differentiating between healthy women and OC patients regardless of their mutation status, we found a sensitivity of 94.3% (AUC = 0.981; p = 6.4e-20;</s><s>We then investigated if these 5 biomarkers are able to differentiate between wildtype and BRCA1 mutation carriers and found a sensitivity of 88.4% at a specificity of 80.7% (AUC = 0.895; p = 6e-08) in the healthy subgroup (Fig <ref type="figure" target="#fig_4">2D</ref>) and a sensitivity of 66.7% at a specificity of 67.8% (AUC = 0.724; p = 0.00065) in the subgroup of OC patients (Fig <ref type="figure" target="#fig_4">2E</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>To date, screening for OC in women at high risk consists of the combination of CA125 and TVU, although evidence is insufficient to demonstrate that these tests provide a survival benefit <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b8">9]</ref>.</s><s>Improvement of OC screening strategies in high risk women is urgently warranted not only for BRCA1 mutation carriers who decide to postpone or forego RRSO, but also for women with a family history who should follow early detection programs for breast and ovarian cancer.</s><s>We here present the first study comparing the serum levels of a combination of five biomarkers (MIF, leptin, OPN, CA125 and HE4) in healthy wildtype women, healthy BRCA1 mutation carriers, wildtype OC patients and BRCA1 mutation carriers with OC.</s></p><p><s>Our data demonstrate that an algorithm based on these five proteins is able to significantly differentiate between healthy and OC patients in wildtype patients as well as BRCA1 mutation carriers.</s></p><p><s>In average risk women, a wide range of diagnostic approaches like panels of biomarkers, algorithms, ultrasound and other imaging methods have been investigated to improve the early detection of OC <ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref>.</s></p><p><s>Concentrating on biomarkers, HE4 has been reported to be superior to CA125 in separating benign, borderline ovarian tumors, cancers of the fallopian tubes, as well as early stage epithelial OC <ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref><ref type="bibr" target="#b32">[33]</ref><ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref><ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref>.</s><s>Together with CA125 and menopausal status it has been incorporated into the Risk of Ovarian Malignancy Algorithm (ROMA) <ref type="bibr" target="#b39">[40]</ref> and in combination with CA125-II, apolipoprotein A-1, follicle stimulating hormone, and transferrin into the Overa-Test in order to discern malignant from benign pelvic masses <ref type="bibr" target="#b40">[41]</ref>.</s></p><p><s>Osteopontin is another interesting biomarker, which has been shown to ameliorate the discriminating ability between benign and malign pelvic masses when combined with HE4 and CA125 <ref type="bibr" target="#b41">[42]</ref>.</s><s>Furthermore, El-Tanani MK et al demonstrated that BRCA1 mutation lead to OPN overexpression resulting in proliferation of breast cancer cells in a rat mammary model system <ref type="bibr" target="#b42">[43]</ref>, thus OPN could also be an important biomarker in the development of OC in BRCA1 mutation carriers.</s></p><p><s>There is some evidence that lower levels of leptin <ref type="bibr" target="#b43">[44]</ref> and higher levels of prolactin [45] might be associated with increased risk of ovarian cancer.</s></p><p><s>The combination of the above mentioned six biomarkers (MIF, OPN, CA125, IGF II, leptin and prolactin) has been shown to improve differentiation between disease free and ovarian cancer patients compared to CA125 alone in patients without a family history of OC <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>.</s><s>Other studies reported similar benefits when combining these six biomarkers with p53 <ref type="bibr" target="#b45">[46]</ref> or interleukin 18 (IL-18) and fibroblast growth factor 2 (FGF-2) <ref type="bibr" target="#b46">[47]</ref>.</s></p><p><s>Although these developments seem to be promising, recent data suggest that CA125 is still the best single marker for the early detection of OC <ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref><ref type="bibr" target="#b49">[50]</ref> in average risk women and limited data exists regarding the use of these biomarkers as OC screening in high risk women.</s></p><p><s>In high risk women, it has been suggested that higher cut-off levels and frequent CA125 testing could improve the low sensitivity and specificity of the current early detection program <ref type="bibr" target="#b50">[51]</ref>.</s><s>Our data, which show significantly higher levels of CA125 in healthy BRCA1 mutation carriers and lower levels of leptin when compared to healthy wildtype women, confirm the suggested necessity of individual adjustment of CA125 cut-off levels.</s></p><p><s>Our study has several limitations like the small sample size and the possible laboratory or sampling bias, because samples have been obtained from two different biobanks.</s><s>Although all OC samples have been collected prior to surgery following a standardized protocol in the two centers, we performed a test for interaction and found no significant difference for CA125, leptin, OPN, MIF, IGF2 and HE4.</s><s>However, the prolactin levels differed significantly between the two centers and we therefore excluded prolactin from our algorithm.</s></p><p><s>Furthermore our study is limited by the difference in age between healthy BRCA1 mutation carriers and those with OC as age could impact the expression of biomarkers.</s><s>While we found a positive correlation of the level of MIF in the healthy wildtype group, we found no such correlation in healthy BRCA1 mutation carriers or those with OC.</s><s>We found slightly higher levels of MIF in the healthy wildtype group (oldest cohort) compared to the healthy BRCA1 mutation carriers (youngest cohort), but in both OC groups (WT and BRCA1) the levels of MIF were significantly higher than in the healthy control groups.</s><s>Furthermore, we found a negative correlation between the levels of IGF2 and age and therefore suggest that the higher levels of IGF2 (p = n.s.) in healthy BRCA1 mutation carriers result from the younger age in this group.</s></p><p><s>Taken together we have developed an algorithm, which can differentiate between healthy women and OC patients with a sensitivity of 94.3% and a specifity of 92.3% and have for the first time shown, that such an algorithm can also be used in BRCA mutation carriers with a sensitivity of 95.2% and a specifity of 92.3%.</s></p><p><s>However, to verify if this algorithm could improve the early detection of OC in high risk women, larger prospective trials with mainly early stage OC cases are warranted.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting information</head><note type="other">S1</note></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>).</s><s>The individual serum levels of the evaluated biomarkers are shown in Fig 1A-1F.</s><s>CA125 (Fig 1A) and MIF (Fig 1B) were shown to be the best single markers to differentiate between healthy women and OC patients in wildtype as well as BRCA1 mutation carriers (MIF: p = 4.64e-16; CA-125: p = 9.19e-23, respectively) followed by Leptin (p = 0.00000108; Fig 1C).</s><s>While different levels of HE4 (Fig 1D) lead to a significant difference between healthy wildtype women and wildtype OC patients (p = 0.000898), we found no significant difference in the HE4 levels of healthy BRCA1 mutation carriers and those with OC.</s><s>We found no significant differences between the four groups comparing their levels of IGF2 (P = 0.138; Fig 1E) or OPN (p = 0.528; Fig 1F).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>Fig 1A) and lower levels of Leptin (Fig 1E) in BRCA1 mutation carriers.</s><s>In the OC cohort, Leptin was the only biomarker with significantly different (lower) levels between wildtype OC patients and BRCA1 mutation carriers (Fig 1E).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>Fig 2A).</s><s>We then calculated the ROC AUC separetely for the wildtype subgroup showing a sensitivity of 92.8% (AUC = 0.988; p = 5.2e-14; Fig 2B) and the subgroup of BRCA1 mutation carriers resulting in a sensitivity of 95.2% (AUC = 0.978; p = 1.7e-15;</s><s>Fig 2C) at an overall sensitivity of 92.3%.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig 1 .</head><label>1</label><figDesc><div><p><s>Fig 1. Serum levels of the six biomarkers.</s><s>Different serum levels of CA125 (A), MIF (B), Leptin (C), HE4 (D), IGF2 (E), OPN (F) in the four groups (Co WT = healthy wildtype, Co BRCA = healthy BRCA1 mutation carriers, CaWT = wildtype ovarian cancer patients, CaBRCA = BRCA1 mutation carriers with ovarian cancer).</s><s>https://doi.org/10.1371/journal.pone.0189641.g001</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Fig 2 .</head><label>2</label><figDesc><div><p><s>Fig 2. Sensitivity and specificity.</s><s>Sensitivity and specificity of the combination of five biomarkers (CA125, MIF, Leptin, HE4, OPN) in differentiating between healthy women and OC patients (A), healthy wildtype women and wildtype OC patients (B), healthy BRCA1 mutation carriers and BRCA1 mutation carriers with OC (C), healthy wildtype women and healthy BRCA1 mutation carriers (D) and wildtype OC patients and BRCA1 mutation carriers with OC (E).</s><s>https://doi.org/10.1371/journal.pone.0189641.g002</s></p></div></figDesc><graphic coords="7,38.15,78.01,537.73,552.42" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head></head><label></label><figDesc><div><p><s>Fig. Serum levels of prolactin.</s><s>Different serum levels of Prolactin with significant differences between samples from the two biobanks (Vienna and Berlin).</s><s>We therefore excluded Prolactin from our calculations.</s><s>(PNG) S2 Fig. Correlations of the investigated biomarkers with age in the Co WT group.</s><s>Correlation coefficient (R); ˚p&lt;0.1 (not sign.);</s><s>Ã p&lt;0.05;</s><s>ÃÃ p &lt;0.01; ÃÃÃ p &lt;0.001(Spearman).</s><s>(TIFF) S3 Fig. Correlations of the investigated biomarkers with age in the CA WT group.</s><s>Correlation coefficient (R); ˚p&lt;0.1 (not sign.);</s><s>Ã p&lt;0.05;</s><s>ÃÃ p &lt;0.01; ÃÃÃ p &lt;0.001(Spearman).</s><s>(TIFF) S4 Fig. Correlations of the investigated biomarkers with age in the Co BRCA1 group.</s><s>Correlation coefficient (R); ˚p&lt;0.1 (not sign.);</s><s>Ã p&lt;0.05;</s><s>ÃÃ p &lt;0.01; ÃÃÃ p &lt;0.001(Spearman).</s><s>(TIFF) S5 Fig. Correlations of the investigated biomarkers with age in the CA BRCA1 group.</s><s>Correlation coefficient (R); ˚p&lt;0.1 (not sign.);</s><s>Ã p&lt;0.05;</s><s>ÃÃ p &lt;0.01; ÃÃÃ p &lt;0.001(Spearman).</s><s>(TIFF)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 . Patients characteristics of the healthy control group (wildtype and BRCA1) and patients tumor characteristics of the group of ovarian cancer patients (wildtype and BRCA1).</head><label>1</label><figDesc></figDesc><table><row><cell></cell><cell>Wildtype</cell><cell>BRCA1</cell><cell>Wildtype</cell><cell>BRCA1</cell></row><row><cell></cell><cell>healthy</cell><cell>healthy</cell><cell>OC</cell><cell>OC</cell></row><row><cell></cell><cell>(n = 26)</cell><cell>(n = 26)</cell><cell>(n = 28)</cell><cell>(n = 26)</cell></row><row><cell>Median age (yrs)</cell><cell>67.1</cell><cell>36.4</cell><cell>57.6</cell><cell>53.0</cell></row><row><cell>(range)</cell><cell>(60.7-72.4)</cell><cell>(26.4-61.7)</cell><cell>(33.6-82.1)</cell><cell>(41.0-78.0)</cell></row><row><cell>OC histology</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>serous</cell><cell></cell><cell></cell><cell>23 (82.1%)</cell><cell>22 (84.6%)</cell></row><row><cell>mucinous</cell><cell></cell><cell></cell><cell>0 (0.0%)</cell><cell>1 (3.8%)</cell></row><row><cell>endometroid</cell><cell></cell><cell></cell><cell>2 (7.2%)</cell><cell>1 (3.8%)</cell></row><row><cell>NA</cell><cell></cell><cell></cell><cell>3 (10.7%)</cell><cell>2 (7.8%)</cell></row><row><cell>Grading</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>G1</cell><cell></cell><cell></cell><cell>0 (0.0%)</cell><cell>0 (0.0%)</cell></row><row><cell>G2</cell><cell></cell><cell></cell><cell>6 (21.4%)</cell><cell>7 (26.9%)</cell></row><row><cell>G3</cell><cell></cell><cell></cell><cell>20 (71.4%)</cell><cell>19 (73.1%)</cell></row><row><cell>NA</cell><cell></cell><cell></cell><cell>2 (7.2%)</cell><cell>0 (0.0%)</cell></row><row><cell>FIGO</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>1a</cell><cell></cell><cell></cell><cell>0 (0.0%)</cell><cell>1 (3.8%)</cell></row><row><cell>1b</cell><cell></cell><cell></cell><cell>0 (0.0%)</cell><cell>0 (0.0%)</cell></row><row><cell>1c</cell><cell></cell><cell></cell><cell>0 (0.0%)</cell><cell>2 (7.8%)</cell></row><row><cell>2a</cell><cell></cell><cell></cell><cell>1 (3.6%)</cell><cell>0 (0.0%)</cell></row><row><cell>2b</cell><cell></cell><cell></cell><cell>1 (3.6%)</cell><cell>0 (0.0%)</cell></row><row><cell>2c</cell><cell></cell><cell></cell><cell>1 (3.6%)</cell><cell>0 (0.0%)</cell></row><row><cell>3a</cell><cell></cell><cell></cell><cell>1 (3.6%)</cell><cell>0 (0.0%)</cell></row><row><cell>3b</cell><cell></cell><cell></cell><cell>6 (21.4%)</cell><cell>0 (0.0%)</cell></row><row><cell>3c</cell><cell></cell><cell></cell><cell>14 (50.0%)</cell><cell>19 (73.0%)</cell></row><row><cell>4</cell><cell></cell><cell></cell><cell>4 (14.2%)</cell><cell>4 (15.4%)</cell></row></table><note><p><s>Abbreviations: OC = ovarian cancer https://doi.org/10.1371/journal.pone.0189641.t001</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 . Correlations of the levels of the investigated biomarkers with age in the four study groups.</head><label>2</label><figDesc></figDesc><table><row><cell>age</cell><cell>CA125</cell><cell>MIF</cell><cell>Leptin</cell><cell>HE4</cell><cell>IGF2</cell><cell>OPN</cell><cell>Prolactin</cell></row><row><cell>Co WT</cell><cell>67,1</cell><cell>0,42</cell><cell></cell><cell></cell><cell>-0,35</cell><cell></cell><cell></cell></row><row><cell>Co BRCA1</cell><cell>36,4</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CA WT</cell><cell>57,6</cell><cell></cell><cell></cell><cell>0,49</cell><cell>-0,50</cell><cell>0,47</cell><cell></cell></row><row><cell>CA BRCA1</cell><cell>53,0</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>bold: p&lt;0.05, bold, italic: p&lt;0.100, black: not sign.</s><s>https://doi.org/10.1371/journal.pone.0189641.t002</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS ONE | https://doi.org/10.1371/journal.pone.0189641December 15, 2017  </note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author Contributions</head><p><s>Conceptualization: Daphne Gschwantler-Kaulich, Robert Zeilinger, Dietmar Pils, Christian F. Singer.</s></p><p><s>Data curation: Daphne Gschwantler-Kaulich, Sigrid Weingartshofer, Robert Zeilinger, Daniela Muhr, Marie-Therese Kastner, Jalid Sehouli.</s></p><p><s>Formal analysis: Sigrid Weingartshofer, Christine Rappaport-Fu ¨rhauser, Dietmar Pils, Daniela Muhr, Marie-Therese Kastner.</s></p><p><s>Funding acquisition: Daphne Gschwantler-Kaulich, Christian F. Singer.</s></p><p><s>Investigation: Daphne Gschwantler-Kaulich, Marie-Therese Kastner, Christian F. Singer.</s></p><p><s>Methodology: Daphne Gschwantler-Kaulich, Sigrid Weingartshofer, Christine Rappaport-Fu ¨rhauser, Robert Zeilinger, Dietmar Pils, Christian F. Singer.</s></p><p><s>Project administration: Daphne Gschwantler-Kaulich, Christian F. Singer.</s></p><p><s>Resources: Daphne Gschwantler-Kaulich, Sigrid Weingartshofer, Robert Zeilinger, Daniela Muhr, Elena I. Braicu, Jalid Sehouli.</s></p><p><s>Software: Dietmar Pils.</s></p><p><s>Supervision: Daphne Gschwantler-Kaulich, Robert Zeilinger, Christian F. Singer.</s></p><p><s>Validation: Daphne Gschwantler-Kaulich, Christine Rappaport-Fu ¨rhauser, Robert Zeilinger, Yen Y. Tan, Christian F. Singer.</s></p><p><s>Visualization: Sigrid Weingartshofer, Dietmar Pils, Lorenz Semmler.</s></p><p><s>Writing -original draft: Daphne Gschwantler-Kaulich.</s></p><p><s>Writing -review &amp; editing: Elena I. Braicu, Yen Y. Tan, Christian F. Singer.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer Screening in the United States, 2017: A review of current american cancer society guidelines and current issues in cancer screening</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Brooks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Fedewa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Manassaram-Baptiste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Saslow</surname></persName>
		</author>
		<idno type="DOI">10.3322/caac.21392</idno>
		<idno type="PMID">28170086</idno>
		<ptr target="https://doi.org/10.3322/caac.21392" />
	</analytic>
	<monogr>
		<title level="j">Ca Cancer J Clin</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="100" to="121" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Marks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Mandell</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.1088759</idno>
		<idno type="PMID">14576434</idno>
		<ptr target="https://doi.org/10.1126/science.1088759" />
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">302</biblScope>
			<biblScope unit="page" from="643" to="646" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Clinical Practice Guidline for the prevention and early detection of breast and ovarian caner in women from HBOC (hereditary breast and ovarian cancer) families</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Singer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Tea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pristauz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hubalek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rappaport</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Riedl</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00508-015-0880-x</idno>
		<idno type="PMID">26525377</idno>
		<ptr target="https://doi.org/10.1007/s00508-015-0880-x" />
	</analytic>
	<monogr>
		<title level="j">Wien Klin Wochenschr</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="981" to="986" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Riedl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Luft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bernhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bernathova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Tea</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2014.56.8626</idno>
		<idno type="PMID">25713430</idno>
		<ptr target="https://doi.org/10.1200/JCO.2014.56.8626" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1128" to="1135" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Progress and challenges in screening for early detection of ovarian cancer</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Menon</surname></persName>
		</author>
		<idno type="DOI">10.1074/mcp.R400006-MCP200</idno>
		<idno type="PMID">14764655</idno>
		<ptr target="https://doi.org/10.1074/mcp.R400006-MCP200" />
	</analytic>
	<monogr>
		<title level="j">Mol Cell Proteomics</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="355" to="366" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wilder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pavlik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Straughn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynaecol Oncol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="page" from="233" to="235" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Ultrasound screening for the early detection of ovarian cancer</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Depriest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Desimone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="194" to="199" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Sensitivity and specificity of mulitmodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK-Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)</title>
		<author>
			<persName><forename type="first">U</forename><surname>Menon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gentry-Maharaj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hallett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Burnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1470-2045(09)70026-9</idno>
		<idno type="PMID">19282241</idno>
		<ptr target="https://doi.org/10.1016/S1470-2045(09)70026-9" />
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="327" to="340" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Buys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Partridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Black</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lamerato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Isaacs</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.2011.766</idno>
		<idno type="PMID">21642681</idno>
		<ptr target="https://doi.org/10.1001/jama.2011.766" />
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">305</biblScope>
			<biblScope unit="page" from="2295" to="2303" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Patrono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Iniesta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Malpica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Salvo</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2015.09.018</idno>
		<idno type="PMID">26407480</idno>
		<ptr target="https://doi.org/10.1016/j.ygyno.2015.09.018" />
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="568" to="572" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Domchek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Friebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Garber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Isaacs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Matloff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Eeles</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10549-010-0799-x</idno>
		<idno type="PMID">20180014</idno>
		<ptr target="https://doi.org/10.1007/s10549-010-0799-x" />
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res Treat</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="195" to="203" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Eisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lubinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Klijn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">T</forename><surname>Lynch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Offit</surname></persName>
		</author>
		<idno type="DOI">10.1200/JCO.2004.00.7138</idno>
		<idno type="PMID">16234515</idno>
		<ptr target="https://doi.org/10.1200/JCO.2004.00.7138" />
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="7491" to="7496" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Meta-analysis of risk reduction estimates associated with riskreducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Rebbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Kauff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Domchek</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djn442</idno>
		<idno type="PMID">19141781</idno>
		<ptr target="https://doi.org/10.1093/jnci/djn442" />
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="page" from="80" to="87" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Domchek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Friebel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Neuhausen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Isaacs</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1470-2045(06)70585-X</idno>
		<idno type="PMID">16510331</idno>
		<ptr target="https://doi.org/10.1016/S1470-2045(06)70585-X" />
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="223" to="229" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Mannis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Fehninger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Creasman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Jacoby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Beattie</surname></persName>
		</author>
		<idno type="DOI">10.1001/2013.jamainternmed.962</idno>
		<idno type="PMID">23247828</idno>
		<ptr target="https://doi.org/10.1001/2013.jamainternmed.962" />
	</analytic>
	<monogr>
		<title level="j">JAMA Intern Med</title>
		<imprint>
			<biblScope unit="volume">173</biblScope>
			<biblScope unit="page" from="96" to="103" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">HE4 serum levels in patients with BRCA1 gene mutation undergoing prophylactic surgery as well as in other benign and malignant gynecological diseases</title>
		<author>
			<persName><forename type="first">A</forename><surname>Chudecka-Głaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cymbaluk-Płoska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Strojna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Menkiszak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dis Markers</title>
		<imprint>
			<date type="published" when="2017-01-15">2017. 2017. 9792756. 2017 Jan 15</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Y</forename><surname>Karlan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thorpe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Watabayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Drescher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Palomares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Daly</surname></persName>
		</author>
		<idno type="DOI">10.1158/1055-9965.EPI-13-1361</idno>
		<idno type="PMID">24789859</idno>
		<ptr target="https://doi.org/10.1158/1055-9965.EPI-13-1361" />
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiol Biomarkers Prev</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1383" to="1393" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Diagnostic Markers for Early Detection of Ovarian Cancer</title>
		<author>
			<persName><forename type="first">I</forename><surname>Visintin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Longton</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.CCR-07-1569</idno>
		<idno type="PMID">18258665</idno>
		<ptr target="https://doi.org/10.1158/1078-0432.CCR-07-1569" />
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1065" to="1072" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer-a study of the OVCAD consortium</title>
		<author>
			<persName><forename type="first">D</forename><surname>Pils</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Obermayr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Aust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Heinze</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2407-13-178</idno>
		<idno type="PMID">23551967</idno>
		<ptr target="https://doi.org/10.1186/1471-2407-13-178" />
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">178</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Serum protein markers for early detection of ovarian cancer</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Visintin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rutherford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="7667" to="7682" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<monogr>
		<title level="m" type="main">R: A language and environment for statistical computing. R Foundation for Statistical Computing</title>
		<author>
			<persName><forename type="first">R</forename><surname>Development Core</surname></persName>
		</author>
		<author>
			<persName><surname>Team</surname></persName>
		</author>
		<ptr target="http://www.R-project.org" />
		<imprint>
			<date type="published" when="2008">2008</date>
			<pubPlace>Vienna, Austria</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">ROCR: visualizing classifier performance in R</title>
		<author>
			<persName><forename type="first">T</forename><surname>Sing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Sander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Beerenwinkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lengauer</surname></persName>
		</author>
		<idno type="DOI">10.1093/bioinformatics/bti623</idno>
		<idno type="PMID">16096348</idno>
		<ptr target="https://doi.org/10.1093/bioinformatics/bti623" />
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="3940" to="3941" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">OptimalCutpoints: An R Package for Selecting Optimal Cutpoints in Diagnostic Tests</title>
	</analytic>
	<monogr>
		<title level="j">Journal of Statistical Software</title>
		<editor>Monica Lopez-Raton Maria Xose Rodriguez-Alvarez, Carmen Cadarso Suarez Francisco Gude Sampedro</editor>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="1" to="36" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Validation of novel biomarker panel for the detection of ovarian cancer</title>
		<author>
			<persName><forename type="first">F</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Q</forename><surname>Bernardini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Molina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Bast</surname></persName>
		</author>
		<author>
			<persName><surname>Jr</surname></persName>
		</author>
		<idno type="DOI">10.1158/1055-9965.EPI-15-1299</idno>
		<idno type="PMID">27448593</idno>
		<ptr target="https://doi.org/10.1158/1055-9965.EPI-15-1299" />
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiol Biomarkers Prev</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="1333" to="1340" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Fortner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Vitonis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hu ¨sing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Fichorova</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13048-017-0315-6</idno>
		<idno type="PMID">28320479</idno>
		<ptr target="https://doi.org/10.1186/s13048-017-0315-6" />
	</analytic>
	<monogr>
		<title level="j">J Ovarian Res</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">20</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Diagnostic performance of Risk of Ovarian Cancer Algorithm against CA125 and HE4 in connection with ovarian cancer: a meta-analysis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Dayyani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Uhlig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Colson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rolny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Morgenstern</surname></persName>
		</author>
		<idno type="DOI">10.1097/IGC.0000000000000804</idno>
		<idno type="PMID">27540691</idno>
		<ptr target="https://doi.org/10.1097/IGC.0000000000000804" />
	</analytic>
	<monogr>
		<title level="j">Int J Gynecol Cancer</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="1586" to="1593" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">A perspective on ovarian cancer biomarkers: past, present and yet-to-come</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Ueland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagnostics</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">14</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer</title>
		<author>
			<persName><forename type="first">El</forename><surname>Bairi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kandhro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Gouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mahfoud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Louanjli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Saadani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Oncol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="105" to="118" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">HE4 in the differential diagnosis of ovarian masses</title>
		<author>
			<persName><forename type="first">T</forename><surname>Granato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Porpora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Longo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Angeloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Manganaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Anastasi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cca.2015.03.047</idno>
		<idno type="PMID">25892674</idno>
		<ptr target="https://doi.org/10.1016/j.cca.2015.03.047" />
	</analytic>
	<monogr>
		<title level="j">Clin Chim Acta</title>
		<imprint>
			<biblScope unit="volume">446</biblScope>
			<biblScope unit="page" from="147" to="155" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis; a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Macedo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Da Rosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lumertz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Meeiros</surname></persName>
		</author>
		<idno type="DOI">10.1097/IGC.0000000000000192</idno>
		<idno type="PMID">25078339</idno>
		<ptr target="https://doi.org/10.1097/IGC.0000000000000192" />
	</analytic>
	<monogr>
		<title level="j">Int J Gynecol Cancer</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1222" to="1231" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">D</forename><surname>Yin</surname></persName>
		</author>
		<idno type="PMID">23317195</idno>
	</analytic>
	<monogr>
		<title level="j">Asian Pac J Cancer Prev</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="5427" to="5432" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yang</surname></persName>
		</author>
		<idno type="DOI">10.1097/IGC.0b013e318263efa2</idno>
		<idno type="PMID">22854652</idno>
		<ptr target="https://doi.org/10.1097/IGC.0b013e318263efa2" />
	</analytic>
	<monogr>
		<title level="j">Int J Gynecol Cancer</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1106" to="1112" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">The use of multiple novel tumor biomarkers for the detection of ovarian cancer in patients with a pelvic mass</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Miller</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2007.10.017</idno>
		<idno type="PMID">18061248</idno>
		<ptr target="https://doi.org/10.1016/j.ygyno.2007.10.017" />
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="page" from="402" to="408" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Disilvestro</surname></persName>
		</author>
		<idno type="DOI">10.1097/AOG.0b013e318224fce2</idno>
		<idno type="PMID">21775843</idno>
		<ptr target="https://doi.org/10.1097/AOG.0b013e318224fce2" />
	</analytic>
	<monogr>
		<title level="j">Obstet Gynecol</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page" from="280" to="288" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ferraro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Braga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lanzoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Boracchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Biganzoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Panteghini</surname></persName>
		</author>
		<idno type="DOI">10.1136/jclinpath-2012-201031</idno>
		<idno type="PMID">23426716</idno>
		<ptr target="https://doi.org/10.1136/jclinpath-2012-201031" />
	</analytic>
	<monogr>
		<title level="j">J Clin Pathol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="273" to="281" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review</title>
		<author>
			<persName><forename type="first">G</forename><surname>Scaletta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Plotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Luvero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Capriglione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Montera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Miranda</surname></persName>
		</author>
		<idno type="DOI">10.1080/14737140.2017.1360138</idno>
		<idno type="PMID">28756722</idno>
		<ptr target="https://doi.org/10.1080/14737140.2017.1360138" />
	</analytic>
	<monogr>
		<title level="j">Expert Rev Anticancer Ther</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="827" to="839" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?</title>
		<author>
			<persName><forename type="first">R</forename><surname>Angioli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Plotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Capriglione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Aloisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Montera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Luvero</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2012.11.040</idno>
		<idno type="PMID">23220563</idno>
		<ptr target="https://doi.org/10.1016/j.ygyno.2012.11.040" />
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="579" to="583" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Does HE4 have a role as biomarker in the recurrence of ovarian cancer?</title>
		<author>
			<persName><forename type="first">F</forename><surname>Plotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Capriglione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Terranova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Montera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Aloisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Damiani</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13277-012-0471-7</idno>
		<idno type="PMID">22875782</idno>
		<ptr target="https://doi.org/10.1007/s13277-012-0471-7" />
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="2117" to="2123" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature</title>
		<author>
			<persName><forename type="first">S</forename><surname>Capriglione</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Luvero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Plotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Terranova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Montera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Scaletta</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12032-017-1026-y</idno>
		<idno type="PMID">28825178</idno>
		<ptr target="https://doi.org/10.1007/s12032-017-1026-y" />
	</analytic>
	<monogr>
		<title level="j">Med Oncol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page">164</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Terlikowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dobrzycka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Witkowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Mackowiak-Matejczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Sledziewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kinalski</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13048-016-0254-7</idno>
		<idno type="PMID">27436085</idno>
		<ptr target="https://doi.org/10.1186/s13048-016-0254-7" />
	</analytic>
	<monogr>
		<title level="j">J Ovarian Res</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">43</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses</title>
		<author>
			<persName><forename type="first">R</forename><surname>Coleman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Herzog</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Munroe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Pappas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Obstet Gynecol</title>
		<imprint>
			<biblScope unit="volume">215</biblScope>
			<biblScope unit="page" from="82" to="e83" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note>e11</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Diagnostic value of serum angiogenesis markers in ovarian cancer using Multiplex Immunoassay</title>
		<author>
			<persName><forename type="first">A</forename><surname>Horala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Swiatly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Matysiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Banach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Nowak-Markwitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">J</forename><surname>Kokot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Mol Sci</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">123</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">BRCA1 suppresses osteopontin-mediated breast cancer</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>El-Tanani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Crowe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Erwin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Harkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Pharoah</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.M604403200</idno>
		<idno type="PMID">16807234</idno>
		<ptr target="https://doi.org/10.1074/jbc.M604403200" />
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope unit="page" from="26587" to="26601" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.5468/ogs.2016.59.4.279</idno>
		<idno type="PMID">27462594</idno>
		<ptr target="https://doi.org/10.5468/ogs.2016.59.4.279" />
	</analytic>
	<monogr>
		<title level="j">Obstet Gynecol Sci</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="279" to="285" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Circulating prolactin levels and risk of epithelial ovarian cancer</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">V</forename><surname>Clendenen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Arslan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Lokshin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lundin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Koenig</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10552-013-0156-6</idno>
		<idno type="PMID">23378139</idno>
		<ptr target="https://doi.org/10.1007/s10552-013-0156-6" />
	</analytic>
	<monogr>
		<title level="j">Cancer Causes Control</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="741" to="748" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Comparison of cancidate serologic markers for type I and type II ovarian cancer</title>
		<author>
			<persName><forename type="first">D</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kuhn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Bristow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">I</forename><surname>Giuntoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kru</forename><surname>Rl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>¨ger Kjaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I-M</forename><surname>Shih</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ygyno.2011.05.039</idno>
		<idno type="PMID">21704359</idno>
		<ptr target="https://doi.org/10.1016/j.ygyno.2011.05.039" />
	</analytic>
	<monogr>
		<title level="j">Gynecol Oncol</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="page" from="560" to="566" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Combination of serum biomarkers to differentiate malignant from benign ovarian tumors</title>
		<author>
			<persName><forename type="first">G</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Holcroft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Beauchamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yasmeen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ferenczy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kendall-Dupont</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1701-2163(16)35273-2</idno>
		<idno type="PMID">22673173</idno>
		<ptr target="https://doi.org/10.1016/S1701-2163(16)35273-2" />
	</analytic>
	<monogr>
		<title level="j">J Obstet Gynaecol Can</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="567" to="574" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">EPIC early detection of ovarian cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Skates</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.CCR-16-1391</idno>
		<idno type="PMID">27418634</idno>
		<ptr target="https://doi.org/10.1158/1078-0432.CCR-16-1391" />
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="4542" to="4544" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Terry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Fortner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hu ¨sing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Fichorova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Yamamoto</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.CCR-16-0316</idno>
		<idno type="PMID">27060155</idno>
		<ptr target="https://doi.org/10.1158/1078-0432.CCR-16-0316" />
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="4664" to="4675" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancers: Updated Guidelines From the European Group on Tumor Markers</title>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Duffy</forename><forename type="middle">Mj</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Othman Abu</forename><surname>Hassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Verheijen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Tholander</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Jr</surname></persName>
		</author>
		<idno type="DOI">10.1097/IGC.0000000000000586</idno>
		<idno type="PMID">26588231</idno>
		<ptr target="https://doi.org/10.1097/IGC.0000000000000586" />
	</analytic>
	<monogr>
		<title level="j">Int J Gynecol Cancer</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="43" to="51" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Early detection of ovarian cancer using the Risk of Ovarian Cancer Algorithm with frequent CA125 testing in women at increased familial risk-combined results from two screening trials</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Skates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Greene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Buys</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Mai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Piedmonte</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<date type="published" when="2017-01-31">2017. 2017 Jan 31</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
